[Skip to Content]
[Skip to Content Landing]
Research Letter
February 2016

Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment

Author Affiliations
  • 1Department of Anesthesiology, Walter Reed National Military Medical Center, Bethesda, Maryland
  • 2Division of General Internal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3South Carolina College of Pharmacy, University of South Carolina, Columbia
JAMA Oncol. 2016;2(2):274-276. doi:10.1001/jamaoncol.2015.3928

A 1999 investigation1 found that industry sponsorship of cost-effectiveness analyses (CEAs) for oncology drugs was associated with lower likelihood of reporting unfavorable conclusions relative to CEAs with other sponsorship. Over the past 15 years, the CEA literature for oncology drugs has expanded dramatically, and oncology now accounts for the largest single pharmaceutical sales area worldwide.2 We sought to determine whether the association between industry sponsorship and CEA results has persisted.

First Page Preview View Large
First page PDF preview
First page PDF preview